Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Fabrice Barlési, K. Park, Fortunato Ciardiello et al. · Annals of Oncology · 2016

Cited by 71 works. doi:10.1093/annonc/mdw435.43 Open-access PDF

Authors